Physician profile
Christopher Snyder
NPI 1205270725
$1,401.11
in general payments reported to CMS, 2019-2025
9 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2021: $276 · 2023: $332 · 2024: $20.78 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $801.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $395.65 | 2019-2023 | Trulance |
| Abbvie INC. | $324.25 | 2021-2023 | Mavyret |
| Novo Nordisk INC | $123.83 | 2025 | Wegovy |
| Supernus Pharmaceuticals, INC. | $120.16 | 2025 | Qelbree |
| Phathom Pharmaceuticals, INC. | $117.31 | 2025 | Voquezna |
| Sunovion Pharmaceuticals INC. | $115.41 | 2019 | |
| Intercept Pharmaceuticals, INC. | $96.27 | 2019 | |
| Janssen Biotech, INC. | $87.45 | 2025 | Tremfya |
| Lilly USA, LLC | $20.78 | 2024 | Olumiant, Taltz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.